Positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery announced by Samsara Vision
Results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively.
(Image credit: Adobe Stock / ©Photocreo Bednarek)
Samsara Vision has reported intermediate-term visual and safety outcomes of the SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) in patients 6 months post-surgery. According to the company, SING IMT implantation improved distance and near vision, with a low impact on the corneal endothelium cell density and manageable safety outcomes.
Furthermore, results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively. The percentage of patients able to read at near distance increased from 28.6% at baseline to 97.1% at 6 months, with distance vision also being improved by ⁓3 lines at 6 months post-surgery.
The retrospective SING IMT study included 35 patients (55 years or older) with late-stage age-related macular degeneration (AMD). Starting 6 weeks after surgery, patients participated in a required rehabilitation program, attending 8 90-minute sessions every 2-to-3 weeks for 6 months to optimize their visual outcomes.
No clinically meaningful change from baseline was measured in intraocular pressure or anterior chamber depth. The mean (SD) change from baseline in corneal endothelial cell density at 6 months in operated eyes was -280.7 (315.9) cells/mm2 (-11.4 %).
"This 6-month review highlights the potential of SING IMT to restore meaningful vision to individuals blinded by AMD, while preserving long-term corneal health with its innovative design," said Prof. Toro, co-author of the study from University Hospital Federico II, Naples, Italy.
The SING MT is approved for use in CE Mark referenced countries, with 19 CE referenced countries having implanted the SING IMT in more than 400 patients.
